Catastrophic Antiphospholipid Syndrome (CAPS)
Many patients who develop this rare complication have lupus, and infections have been reported to potentially increase a patient’s risk to develop the syndrome. Even with the best treatment, as many as half the patients who develop this syndrome do not survive.
Treatment includes anticoagulation (blood thinners), steroids, and a procedure called ‘plasma exchange’. Plasma exchange refers to a process whereby a patient’s plasma (the liquid part of the blood) is removed and replaced with plasma from blood donors. Patients who survive this life-threatening complication are generally maintained on long-term anticoagulant therapy.
The above information is located at: http://rarediseasesnetwork.epi.usf.edu/rtdc/learnmore/index.htm#storm
Reproduced with permission by the Rare Thrombotic Diseases Consortium.
Other Catastrophic Antiphospholipid Syndrome (CAPS) Information Resources:
- Catastrophic Antiphospholipid Syndrome (CAPS)
Juan Javier Lichauco, M.D., Jayashree Sinha, M.D.,, and Peter Barland, M.D. February 2002
- Catastrophic Antiphospholipid Syndrome
http://jic.sagepub.com/cgi/reprint/21/3/144 (registration required)
Journal of Intensive Care Medicine, Vol. 21, No. 3, 144-159 (2006). DOI: 10.1177/0885066606287041. Â© 2006 SAGE Publications
- Long term outcome of catastrophic antiphospholipid syndrome survivors
http://ard.bmjjournals.com/cgi/content/full/62/6/530 (registration required)
Annals of the Rheumatic Diseases 2003;62:530-533 Â© 2003 by BMJ Publishing Group & European League Against Rheumatism. Conclusion: Sixty six per cent of patients who survive an initial catastrophic APS event remained symptom free with anticoagulation during an average follow up of 67.2 months. Twenty six per cent of the survivors developed further APS related events and the mortality rate of these patients was about 25%.
- Registry Improves Understanding of Catastrophic Antiphospholipid Syndrome
(2006) 2, 81-89 – Nature Clinical Practice Rheumatology. Catastrophic antiphospholipid syndrome, a severe form of antiphospholipid syndrome, is associated with a high mortality rate; approximately 50% of patients die from thrombotic diathesis. As discussed in this Review, efforts to facilitate early diagnosis, institute effective treatments in a timely manner, and better understand the causes of this extreme condition are needed to improve patient outcome.
Founded in 2005, the APS Foundation of America, Inc. is dedicated to fostering and facilitating joint efforts in the areas of education, public awareness, research, and patient services for Antiphospholipid Syndrome (APS) in an effective and ethical manner.
APS Foundation of America, Inc.
P. O. Box 801
LaCrosse, WI 54602-0801
[ Contact Form ]
DISCLAIMER: APS Foundation of America, Inc. website is not intended to replace standard doctor-patient visits, physical examination, and medical testing. Information given to members is only an opinion. All information should be confirmed with your personal doctor. Always seek the advice of a trained physician in person before seeking any new treatment regarding your medical diagnosis or condition. Any information received from APS Foundation of America, Inc. website is not intended to diagnose, treat, or cure. This site is for informational purposes only. Please note that we will be listing all donor or purchaser's names on the Donor page of our foundation site. If you do not want your name listed, please contact us to opt out. If you think you may have a medical emergency, call your doctor or 911 immediately.